Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13990634 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL13990630 | 0.96 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL12072337 | 0.96 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL617770 | 0.96 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL1512973 | 0.86 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL21013765 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL24648736 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL15244828 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL5898624 | 0.85 | KMT2A (0.57) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 | |
| SCHEMBL26039743 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1KMT2APOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874739-B1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | VCAM1, ICAM1, CD69 | SMN1; SMN2 2571/4885ALDH1A1 137/4885KMT2A 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.